Eli Lilly and Company (LLY) Q2 2026 Earnings Call Transcript

SA Transcripts 161.53K Followers Follow Eli Lilly and Company ( LLY ) Q2 2026 Earnings Call August 5, 2026 10:00 AM EDT Company Participants Mike Czapar - Director of Investor Relations David Ricks - Chairman & CEO Lucas Montarce - Executive VP & CFO Daniel Skovronsky - Chief Scientific & Product Officer and President of Lilly Research Laboratories Ilya Yuffa - Executive VP and President of Lilly USA & Global Customer Capabilities Patrik Jonsson - Executive VP & President of Lilly International Kenneth Custer - Executive VP & President of Lilly Cardiometabolic Health Jacob Van Naarden - Executive VP, President of Lilly Oncology & Head of Corporate Business Development Conference Call Participants Seamus Fernandez - Guggenheim Securities, LLC, Research Division Asad Haider - Goldman Sachs Group, Inc., Research Division Courtney Breen - Bernstein Institutional Services LLC, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Geoffrey Meacham - Citigroup Inc., Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Akash Tewari - Jefferies LLC, Research Division Michael Yee - UBS Investment Bank, Research Division Terence Flynn - Morgan Stanley, Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Jason Gerberry - BofA Securities, Research Division Louise Chen - Scotiabank Global Banking and Markets, Research Division David Risinger - Leerink Partners LLC, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2026 Earnings Conference Call. [Operator Instructions] I would now like to turn the conference over to your host, Mike Czapar, Senior Vice President of Investor Relations. Please go ahead. Mike Czapar Director of Investor Relations Good morning. Thank you for joining us for Eli Lilly and Company's Q2 2026 Earnings Call. I'm Mike Czapar, Senior Vice President of Investor Relations. Joining me on today's call are Dave Ricks, Lilly's Chair and CEO; Lucas Montarce, Chief Financial Officer; Dr. Dan Skovronsky, Chief Scientific and Product Officer; Adrienne Brown, President of Lilly Immunology; Dr. Carole Ho, President of Lilly Neuroscience; Ilya Yuffa, President of Lilly USA and Global